Risultati di ricerca
23 dic 2011 · In the multicentre AML96 trial, 586 patients (aged 15–60 years) with AML—excluding those with t(8;21)—who were in complete remission after double induction treatment were consolidated with allogeneic HSCT, autologous HSCT, or chemotherapy containing high-dose cytarabine in a priority-based and risk-adapted manner.
- Markus Pfirrmann, Gerhard Ehninger, Christian Thiede, Martin Bornhäuser, Michael Kramer, Christoph R...
- 2012
Consolidation treatments include chemotherapy with high-dose cytarabine, or allogeneic or autologous haemopoietic stem cell transplantation (HSCT). In a post-hoc analysis of the AML96 trial (NCT00180115), our aim was to differentiate groups of patients according to the treatments that would provide them optimum benefit.
- Markus Pfirrmann, Gerhard Ehninger, Christian Thiede, Martin Bornhäuser, Michael Kramer, Christoph R...
- 2012
1 feb 2012 · Both the AML96 and AML2003 trials were undertaken in accordance with the Declaration of Helsinki and were approved by the ethics committees of the participating institutions. Briefly, patients included in AML96 were given double induction treatment with standard-dose and intermediate-dose cytarabine, mitoxantrone, etoposide, and amsacrine.
- Markus Pfirrmann, Gerhard Ehninger, Christian Thiede, Martin Bornhäuser, Michael Kramer, Christoph R...
- 2012
12 ago 2010 · The AML96 trial included 909 patients with a median age of 67 years (range, 61-87 years). Treatment included cytarabine-based induction therapy followed by 1 consolidation. … We present an analysis of prognostic factors derived from a trial in patients with acute myeloid leukemia older than 60 years.
- Christoph Röllig, Christian Thiede, Martin Gramatzki, Walter Aulitzky, Heinrich Bodenstein, Martin B...
- 2010
31 mag 2011 · The AML96 trial included 1,862 patients ≥ 18 years old with primary and secondary or treatment-related AML and refractory anemia with excess of blasts according to the French-American-British (FAB) classification. All AML FAB subtypes were eligible for study apart from patients with acute promyelocytic leukemia (FAB M3).
- Christoph Röllig, Martin Bornhäuser, Christian Thiede, Franziska Taube, Michael Kramer, Brigitte Moh...
- 2011
23 mag 2011 · Schematic study design of the AML96 trial performed by the Study Alliance Leukemia committee in adult patients with acute myeloid leukemia up to 60 years of age. Patients were assigned to 12 g/m 2 intermediate-dose cytarabine and mitoxantrone (I-MAC) or 36 g/m 2 high-dose cytarabine and mitoxantrone (H-MAC) by a first-line random assignment step.
15 gen 2016 · Detailed treatment descriptions of the three trials were reported previously. 13, 17, 18 In brief, the AML96 trial enrolled adult patients without age restriction, ...
